Covid-19 roundup: Study sug­gests As­traZeneca/Ox­ford boost­er is ef­fec­tive against vari­ants — re­port; IF­P­MA is­sues guid­ance on vac­cine in­equity

As Covid-19 vari­ants con­tin­ue to emerge and spread, sci­en­tists are al­ready think­ing about shots to boost the ef­fi­ca­cy of the first wave of vac­cines — in­clud­ing the ade­n­ovirus-based jab de­vel­oped by Ox­ford Uni­ver­si­ty and As­traZeneca. An un­named source told the Fi­nan­cial Times that a third dose of that vac­cine can “blow through al­most any vari­ant.”

A re­cent study shows promise for a third dose of the As­traZeneca/Ox­ford shot to pro­tect against new vari­ants, sources fa­mil­iar with the tri­al da­ta told the FT. One went so far as to call the an­ti­body re­ac­tion “un­be­liev­able.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.